Equities

DOD Biotech PCL

DOD Biotech PCL

Actions
  • Price (THB)3.12
  • Today's Change0.08 / 2.63%
  • Shares traded1.95m
  • 1 Year change-23.90%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of THB
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments6830162
Total Receivables, Net11257337
Total Inventory15098113
Prepaid expenses--0.570.33
Other current assets, total421213
Total current assets372197626
Property, plant & equipment, net916976967
Goodwill, net0.2500
Intangibles, net505.575.66
Long term investments2.602.602.60
Note receivable - long term000
Other long term assets8.830.500.50
Total assets1,4581,2911,627
LIABILITIES
Accounts payable--8093
Accrued expenses--1714
Notes payable/short-term debt11014977
Current portion long-term debt/capital leases4.922234
Other current liabilities, total513542
Total current liabilities283304259
Total long term debt535873
Total debt169229183
Deferred income tax181112
Minority interest226.48(18)
Other liabilities, total232521
Total liabilities400404346
SHAREHOLDERS EQUITY
Common stock225205205
Additional paid-in capital1,051891891
Retained earnings (accumulated deficit)(218)(209)185
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity1,0588871,281
Total liabilities & shareholders' equity1,4581,2911,627
Total common shares outstanding450411411
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.